Lipodystrophy in Patients with Acromegaly Receiving Pegvisomant-Reference-Cited by-同舟云学术

Lipodystrophy in Patients with Acromegaly Receiving Pegvisomant

Published:2008-09-01 Issue:9 Volume:93 Page:3515-3518
ISSN:0021-972X
Container-title:The Journal of Clinical Endocrinology & Metabolism
language:en
Short-container-title:

Author:

Bonert Vivien S.¹,Kennedy Laurence²,Petersenn Stephan³,Barkan Ariel⁴,Carmichael John¹,Melmed Shlomo¹

Affiliation:

1. Department of Medicine (V.S.B., J.C., S.M.), Cedars-Sinai Medical Center, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California 90048

2. Department of Medicine (L.K.), University of Florida, Gainesville, Florida 32610

3. Division of Endocrinology (S.P.), Medical Center, University of Duisburg-Essen, 47048 Duisburg, Germany

4. Department of Neurosurgery and Division of Metabolism, Endocrinology, and Diabetes (A.B.), University of Michigan Medical Center, Ann Arbor, Michigan 48105

Publisher

The Endocrine Society

Subject

Biochemistry (medical),Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism

Link

http://academic.oup.com/jcem/article-pdf/93/9/3515/9059243/jcem3515.pdf

Reference20 articles.

1. Medical progress: acromegaly.;Melmed;N Engl J Med,2006

2. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.;Trainer;N Engl J Med,2000

3. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.;van der Lely;Lancet,2001

4. Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant.;Drake;Eur J Endocrinol,2003

5. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant.;Barkan;J Clin Endocrinol Metab,2005

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Growth hormone receptor antagonist pegvisomant and its role in the medical therapy of growth hormone excess;Best Practice & Research Clinical Endocrinology & Metabolism;2024-07

2. Case report: Management of pediatric gigantism caused by the TADopathy, X-linked acrogigantism;Frontiers in Endocrinology;2024-02-28

3. Surgical and non-surgical interventions for primary and salvage treatment of growth hormone-secreting pituitary adenomas in adults;Cochrane Database of Systematic Reviews;2024-02-06

4. Efficacy and Safety of Pegvisomant in the Treatment of Acromegaly;Archives of Medical Research;2023-12

5. Pegvisomant: Lessons Learned After 20 Years and Practical Recommendations of Its Use for the Treatment of Acromegaly;Acromegaly;2022